Last updated: February 15, 2026
Overview of the Drug
NDC 75834-0249 corresponds to Alecensa (alectinib), a tyrosine kinase inhibitor developed by Genentech/Roche. It treats ALK-positive non-small cell lung cancer (NSCLC). The drug gained approval from the FDA in 2017 for previously treated metastatic ALK-positive NSCLC.
Market Context
- Market Size: The global NSCLC drug market was valued at approximately $15 billion in 2022, with targeted therapies like Alecensa capturing a growing share.
- Patient Population: Estimated 10-15% of NSCLC cases are ALK-positive, affecting an estimated 90,000-135,000 newly diagnosed patients globally annually.
- Competitive Landscape: Key competitors include Pfizer’s Xalkori (crizotinib), Novartis’ensartinib, and other emerging agents like brigatinib and lorlatinib.
Market Penetration and Adoption
- Current Use: Alecensa is recommended as a first-line treatment in patients with ALK-positive NSCLC, following pivotal trials like ALEX (2017).
- Prescription Trends: Growing adoption driven by superior CNS penetration compared to competitors; as of 2022, approximately 60% of ALK-positive NSCLC patients in the U.S. receive Alecensa as part of targeted therapy.
Pricing Details
- Current Wholesale Acquisition Cost (WAC): Approximately $13,000 to $14,000 per month.
- Per-Patient Cost: Estimated at $156,000 to $168,000 annually, based on treatment duration.
Price Developments
- In 2020, Roche increased Alecensa’s price by roughly 4-6%, aligning with industry inflation.
- Cost-effectiveness analyses suggest value premiums relative to older therapies, supporting sustained pricing power.
Regulatory and Reimbursement Factors
- Reimbursement: Covered predominantly through Medicare/Medicaid and private insurers in the U.S.; negotiated prices impact net prices.
- Outlook: Price adjustments may occur with new indications or novel combinations.
Forecasted Price Trajectory
| Year |
Expected Price Range (Monthly) |
Notes |
| 2023 |
$13,000 - $14,000 |
Current levels |
| 2024 |
$13,500 - $14,500 |
Slight inflation, competitive pressure |
| 2025 |
$14,000 - $15,000 |
Potential price stabilization or moderation with increased competition |
Market Growth Projections
- Compound Annual Growth Rate (CAGR) (2023-2027): ~8-10%, propelled by increased diagnosis rates, expanding indications (e.g., adjuvant settings), and favorable reimbursement policies.
- Volume Growth: Expected to increase by 7-9% annually as healthcare providers adopt Alecensa earlier in treatment.
Price Sensitivity and Influencing Factors
- Competition from next-generation ALK inhibitors may pressure prices.
- Regulatory approvals for new indications might lead to pricing adjustments.
- Biosimilar or generic entrants are unlikely given the complexity of biologics, but patent expirations or legal settlements could alter landscape.
Summary
- Alecensa's market size will expand modestly due to increased diagnosis and treatment adoption.
- Current pricing around $13,000-$14,000 monthly positions it as a premium targeted therapy.
- Future price increases will depend on competition, regulatory changes, and market dynamics, with projections favoring stability or slight increases through 2025.
Key Takeaways
- Alecensa faces limited direct competition but must contend with emerging agents and potential legal or patent challenges.
- Pricing remains high but stable, supported by clinical efficacy and CNS activity.
- Market growth is driven primarily by increased treatment penetration within ALK-positive NSCLC cases.
- Healthcare policy and payer negotiations will influence net prices increasingly.
- Long-term outlook favors sustained revenue streams with incremental price adjustments.
FAQs
-
How does Alecensa compare to its competitors in terms of price?
Alecensa’s monthly wholesale price (~$13,000-$14,000) is generally comparable or slightly higher than first-generation ALK inhibitors like Xalkori (~$10,000-$12,000). It offers advantages in CNS penetration, which supports its premium positioning.
-
What factors could lead to price reductions for Alecensa?
Entry of biosimilars or generics, regulatory pressure, or significant competition with next-generation agents could induce price reductions.
-
Is Alecensa expected to gain new indications that could impact price?
Yes. FDA approvals for adjuvant therapy or earlier line treatments could increase demand and pricing leverage.
-
What is the impact of treatment adherence on market size and price?
Higher adherence sustains revenue and justifies maintained price levels. Non-adherence reduces treatment duration and revenue per patient but is mitigated by the drug’s efficacy profile.
-
How might future patent issues affect Alecensa's market?
Patent expiration or legal challenges could open a pathway for biosimilar competition, pressuring prices downward.
Sources:
[1] IQVIA, 2022. Global Oncology Market Data.
[2] FDA, 2017. Alecensa (alectinib) Approval Letter.
[3] Roche, 2023. Alecensa Prescribing Information.
[4] GlobalData, 2023. Oncology Drug Market Projections.
